High Bacterial Load Predicts Poor Outcomes in Patients with Idiopathic Pulmonary Fibrosis
P L Molyneaux, M J Cox, S A G Willis-Owen, K E Russell, P Mallia, A M Russell, S L Johnston, A U Wells, W O C Cookson, T M Maher, M F Moffatt
Abstract
BackgroundRepetitive alveolar damage and aberrant repair may be important in the development of the fatal condition Idiopathic Pulmonary Fibrosis (IPF). The role played by microorganisms in this cycle is unknown.\n\nMethodsWe consecutively enrolled patients diagnosed with IPF according to international criteria together with healthy smokers, non-smokers and subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) as controls. Subjects underwent bronchoalveolar lavage (BAL) from which genomic DNA was isolated. The V3-V5 region of the bacterial 16S rRNA gene was amplified, allowing quantification of bacterial load and identification of communities by 16S rRNA qPCR and pyrosequencing.\n\nResultsOur 65 IPF patients had 3.9x109 copies of the 16S rRNA gene per ml of BAL, two-fold more than the 1.8x109 copies in 44 sex- and smoking-matched controls (P<0.0001). Baseline BAL bacterial burden predicted Forced Vital Capacity (FVC) decline (P=0.02). Patients in the highest tertile of bacterial burden were at a higher risk of mortality compared to subjects in the lowest tertile (hazard ratio 4.59 (95% CI, 1.05-20); P=0.04).\n\nSequencing yielded 912,883 high quality reads from all subjects. Operational Taxonomic Units (OTUs) representing Haemophilus, Streptococcus, Neisseria and Veillonella were 1.5 to 3.5 fold more abundant in cases than controls (P<0.05). Regression analyses indicated that these specific OTUs as well as bacterial burden associated independently with IPF.\n\nConclusionsIPF is characterised by an increased bacterial burden in BAL that predicts decline in lung function and death. Clinical trials of antimicrobial therapy may determine if microbial burden is causal or not in IPF progression.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Early-stage idiopathic pulmonary fibrosis is characterized by bronchoalveolar accumulation of SPP1+ macrophages
J. Yu, J. Thomas, … A. Schlitzer·bioRxiv·Dec 6, 2023
- Genes, gut microbiome, and lungs: Untangling the web of Idiopathic Pulmonary Fibrosis
Tamara Hernández-Beeftink, Richard J. Allen, … Louise V. Wain·ERJ Open ResearchPeer-reviewed·Mar 12, 2026
- A Simultaneous Inhibition of ID1 and ID3 Protects Against Pulmonary Fibrosis
Samar A. Antar, Eric Mensah, … Yassine Sassi·bioRxiv·Jul 24, 2025
- Mild CF Lung Disease is Associated with Bacterial Community Stability
T. H. Hampton, D. Thomas, … G. O'Toole·bioRxiv·Mar 23, 2021
- Toll-Like-Receptor 5 protects against pulmonary fibrosis by reducing lung dysbiosis
Yosuke Sakamachi, Emma Wiley, … Stavros Garantziotis·Science Translational MedicinePeer-reviewed·Jun 3, 2026
- Bulk RNA-Sequencing of small airway cell cultures from IPF and post-COVID lung fibrosis patients illustrates disease signatures and differential responses to TGF-β1 treatment
K. Uhl, S. Paithankar, … X. Li·bioRxiv·Mar 1, 2023